Fragile X Syndrome Treatment With NNZ-2566 Compared to Placebo

The purpose of this study is to evaluate the safety of an oral administration of NNZ-2566 in adolescent and adult males and to determine its drug properties, such as how it is absorbed and broken down in the body. The study will also explore if NNZ-2566 helps to reduce interfering symptoms of fragile X syndrome. Nationally, 72 subjects are expected to enroll in this study. At Rush University Medical Center, we expect to recruit approximately 14 patients. The treatment will be assigned randomly.

For more information, please contact Jamie Chin (312) 942-0025 or Rebecca Levin (312) 563-6559.

In order to participate you must meet the following criteria:

• Are a male between ages 14 and 40 and have a diagnosis of fragile X syndrome.
• Have some verbal ability.

You will be excluded from the study if any of the following criteria apply to you:

• Are taking more than three psychotropic drugs, have an unstable seizure disorder or a recent change in drug dosing.
• Are unable to swallow liquid medication.

This is a partial list of eligibility requirements.